S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
Log in
NASDAQ:HTGM

HTG Molecular Diagnostics Stock Forecast, Price & News

$5.60
-0.03 (-0.53 %)
(As of 02/26/2021 12:00 PM ET)
Add
Compare
Today's Range
$5.45
Now: $5.60▼
$5.62
50-Day Range
$5.90
MA: $6.72▼
$7.83
52-Week Range
$3.78
Now: $5.60▼
$13.80
Volume738 shs
Average Volume201,823 shs
Market Capitalization$26.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
HTG Molecular Diagnostics logo

Headlines

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology
February 26, 2021 |  finance.yahoo.com
HTG Announces Board of Directors Transition
January 19, 2021 |  finance.yahoo.com
HTG Molecular Diagnostics Announces Certain Preliminary 2020 Unaudited Financial Results
January 5, 2021 |  finance.yahoo.com
HTG Expands Patent Portfolio with New Canadian Patent for its Nuclease Protection Methods for Detection of Nucleotide Variants
December 30, 2020 |  finance.yahoo.com
HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel
December 18, 2020 |  finance.yahoo.com
HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
December 8, 2020 |  finance.yahoo.com
HTG Molecular Diagnostics announced 1:15 reverse stock split
November 23, 2020 |  seekingalpha.com
HTG Announces One-for-Fifteen Reverse Stock Split
November 23, 2020 |  finance.yahoo.com
HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow
November 19, 2020 |  seekingalpha.com
Newsflash: HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Analysts Have Been Trimming Their Revenue Forecasts
November 15, 2020 |  finance.yahoo.com
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q3 2020 Results - Earnings Call Transcript
November 11, 2020 |  seekingalpha.com
HTG Molecular EPS beats by $0.01, misses on revenue
November 10, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTGM
Previous Symbol
CUSIPN/A
CIK1169987
Webwww.htgmolecular.com
Phone877-289-2615
Employees108
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.58
Current Ratio5.74
Quick Ratio5.48

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$19.20 million
Price / Sales1.38
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.19 per share
Price / Book0.90

Profitability

EPS (Most Recent Fiscal Year)($7.65)
Net Income$-19,300,000.00
Net Margins-194.78%
Return on Equity-101.81%
Return on Assets-50.43%

Miscellaneous

Outstanding Shares4,742,000
Market Cap$26.56 million
Next Earnings Date3/24/2021 (Estimated)
OptionableOptionable

MarketRank™

Overall MarketRank™

1.07 out of 5 stars

Medical Sector

954th out of 1,956 stocks

Analytical Instruments Industry

18th out of 29 stocks

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
$5.60
-0.03 (-0.53 %)
(As of 02/26/2021 12:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

Is HTG Molecular Diagnostics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HTG Molecular Diagnostics stock.
View analyst ratings for HTG Molecular Diagnostics or view top-rated stocks.

What stocks does MarketBeat like better than HTG Molecular Diagnostics?

Wall Street analysts have given HTG Molecular Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but HTG Molecular Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a drop in short interest in January. As of January 15th, there was short interest totaling 147,000 shares, a drop of 27.2% from the December 31st total of 201,800 shares. Based on an average daily trading volume, of 219,000 shares, the short-interest ratio is presently 0.7 days. Currently, 3.8% of the company's stock are short sold.
View HTG Molecular Diagnostics' Short Interest.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for HTG Molecular Diagnostics.

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its earnings results on Tuesday, November, 10th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The medical research company had revenue of $1.78 million for the quarter, compared to the consensus estimate of $2.36 million. HTG Molecular Diagnostics had a negative trailing twelve-month return on equity of 101.81% and a negative net margin of 194.78%.
View HTG Molecular Diagnostics' earnings history.

How has HTG Molecular Diagnostics' stock price been impacted by Coronavirus?

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HTGM shares have increased by 1,320.6% and is now trading at $5.60.
View which stocks have been most impacted by COVID-19.

What guidance has HTG Molecular Diagnostics issued on next quarter's earnings?

HTG Molecular Diagnostics updated its FY 2020 Pre-Market earnings guidance on Tuesday, January, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.5-8.5 million, compared to the consensus revenue estimate of $8.03 million.

What price target have analysts set for HTGM?

4 analysts have issued twelve-month price objectives for HTG Molecular Diagnostics' shares. Their forecasts range from $0.70 to $1.50. On average, they anticipate HTG Molecular Diagnostics' share price to reach $1.05 in the next twelve months. This suggests that the stock has a possible downside of 81.3%.
View analysts' price targets for HTG Molecular Diagnostics or view top-rated stocks among Wall Street analysts.

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:
  • Mr. John L. Lubniewski, Pres & CEO (Age 57, Pay $384.87k)
  • Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. and Treasurer (Age 59, Pay $321.37k)
  • Ms. Laura Lee Godlewski, VP of Fin. & Principal Accounting Officer (Age 41)
  • Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 68)
  • Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 61)
  • Dr. Patrick C. Roche, Sr. VP of R&D (Age 68)
  • Mr. Byron T. Lawson, Sr. VP & Chief Commercial Officer (Age 46)
  • Laura Beggrow, Pres of Diagnostics

What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?

11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among HTG Molecular Diagnostics' employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of HTG Molecular Diagnostics' key competitors?

Some companies that are related to HTG Molecular Diagnostics include Astrotech (ASTC), Precipio (PRPO), Scientific Industries (SCND), Pressure BioSciences (PBIO), BioForce Nanosciences (BFNH), Arrayit (ARYC), DiaSys (DYXC), HORIBA (HRIBF), Orthometrix (OMRX) and PositiveID (PSID).
View all of HTGM's competitors.

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cowen Prime Services LLC (9.32%), Samjo Capital LLC (8.05%), Renaissance Technologies LLC (2.02%), GSA Capital Partners LLP (0.95%), Squarepoint Ops LLC (0.54%) and BlackRock Inc. (0.41%).
View institutional ownership trends for HTG Molecular Diagnostics.

Which institutional investors are selling HTG Molecular Diagnostics stock?

HTGM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, Cowen Prime Services LLC, BlackRock Inc., and HighMark Wealth Management LLC.
View insider buying and selling activity for HTG Molecular Diagnostics or view top insider-selling stocks.

Which institutional investors are buying HTG Molecular Diagnostics stock?

HTGM stock was acquired by a variety of institutional investors in the last quarter, including Samjo Capital LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for HTG Molecular Diagnostics or or view top insider-buying stocks.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $5.60.

How much money does HTG Molecular Diagnostics make?

HTG Molecular Diagnostics has a market capitalization of $26.56 million and generates $19.20 million in revenue each year. The medical research company earns $-19,300,000.00 in net income (profit) each year or ($7.65) on an earnings per share basis.

How many employees does HTG Molecular Diagnostics have?

HTG Molecular Diagnostics employs 108 workers across the globe.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is www.htgmolecular.com.

Where are HTG Molecular Diagnostics' headquarters?

HTG Molecular Diagnostics is headquartered at 3430 E. GLOBAL LOOP, TUCSON AZ, 85706.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.


This page was last updated on 2/26/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.